Cataract & Refractive
Santen launches new ...

Santen recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.

Gene therapy for choroideremia may ...
Microglia implicated in inherited ...
Supraciliary microstenting: ...

Retina
Lens opacity AREDS score predicts ...

Researchers using the AREDS lens grading scale have found that long-term clinically relevant outcomes can be predicted by ...

Comparing anti-VEGFs for DME
NICE gives aflibercept provisional ...
Triamcinolone affects OCT ...

Glaucoma
Analyzing corneal asphericity, OCT ...

Corneal asphericity, OCT angiography, and balance control issues in glaucoma patients are analyzed in this industry ...

Low copay of generic PGA may improve ...
Lens extraction should be considered ...
AC is better than EDI for LC visibility

Latest Issue

OTE Articles

Santen launches new preservative-free combination eye drop in the UKSanten recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.
Microglia implicated in inherited retinitis pigmentosaRetinal microglia contribute to rod demise in retinitis pigmentosa—a blinding hereditary retinal disease for which there is currently no approved treatment, according to a recent study.
Gene therapy for choroideremia may be on horizonGene therapy to treat choroideremia is one step closer to reality thanks to a new study.

Advertisement

Patient-reported vision improved by ocriplasminPatients with symptomatic vitreomacular adhesion (VMA) find that a single intravitreal injection of ocriplasmin improves their vision, according to an ancillary analysis of two multicentre randomised clinical trials reported in JAMA Opthalmology.
Google Glass successfully records scleral buckling surgeryGoogle Glass may be the answer for retina surgeons who struggle to record scleral buckling surgery, according to a recent study published in JAMA Ophthalmology.
Supraciliary microstenting: advancing glaucoma treatment in the age of MIGSIn this article, Dr Ianchulev discusses MIGS supraciliary microstenting, a compelling new approach for outflow enhancement that results in sustained reduction of IOP and anti-hypertensive topical medication use in OAG patients.

Advertisement

Real-world experience with the MFR2 IOLDr Thomassen shares his personal experiences with the MFR2 IOL, including reasons why the MFR2 is his lens of preference, clinical findings from a real-life setting and considerations for future use.
Combination glaucoma therapy by drug-eluting lensesIn this article, the authors present their recent findings on drug-eluting, extended-wear contact lenses for glaucoma and discuss how these lenses may provide week-long IOP reduction with just one day of wear.
Challenges and solutions in the management of exfoliative glaucomaExfoliative glaucoma can prove to be a particularly difficult disease for opthalmologists to manage. In this article, aspects of IOP-lowering therapy specific to this type of glaucoma are considered, as well as the range of treatments available and the potential advantages and challenges associated with each therapy.
Aflibercept fares well in treating DMEIntravitreal aflibercept 2 mg every 8 weeks after 5 initial monthly doses (IVT-AFL 2q8) improved visual acuity outcomes in eyes with center-involved diabetic macular edema (DME) to a greater extent than intravitreal ranibizumab 0.5 mg as needed (IVR 0.5 mg PRN), though vascular endothelial growth factor (VEGF) inhibition with either IVT-AFL or IVR is efficacious and appears safe

Advertisement

Advertisement